FIELD: medicine; pharmacology.
SUBSTANCE: invention refers to pharmacology and endocrinology. Disclosed is use of 9-benzyl-2-biphenylimidazo[1,2-a]benzimidazole hydrochloride of formula I as an agent possessing cardio-, endothelial-, nephro-, microangio-, macroangio- and encephaloprotective properties. Agent can be used as an active ingredient in pharmaceutical compositions for preventing and treating cardio-, endothelial-, nephro-, microangio-, macroangio- and encephaloprotective disorders.
EFFECT: higher efficiency of cardio- and endothelium-protective activity with preservation of microangio-, macroangio-, nephro- and encephaloprotective properties in diabetes mellitus.
1 cl, 7 dwg, 13 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF SODIUM SALT OF DIETHYL ESTER OF 4-OXO-1,4-DIHYDROPYRAZOLO[5,1-C]-1,2,4-TRIAZINE-3,8-DICARBOXYLIC ACID, MONOHYDRATE AS DRUG FOR TREATMENT AND PREVENTION OF LATE COMPLICATIONS OF DIABETES MELLITUS | 2019 |
|
RU2765117C2 |
| METHOD FOR CREATING TRANSLATIONAL MODEL OF DIABETIC PHENOTYPE OF CHRONIC HEART FAILURE | 2023 |
|
RU2817822C1 |
| METHOD OF CORRECTION OF STREPTOZOTOCIN-INDUCED DIABETES MELLITUS IN RATS USING A HETEROCYCLIC AMIDE-BASED DRUG | 2018 |
|
RU2687979C1 |
| METHOD FOR MODELING OSTEOPOROSIS WITH STREPTOZOTOCIN-INDUCED DIABETES MELLITUS IN RATS | 2019 |
|
RU2712153C1 |
| 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE AND NICOTINIC ACID SALT, HAVING HYPOGLYCEMIC, HYPOLIPIDEMIC AND NEUROPROTECTIVE ACTIVITY AND SYNTHESIS METHOD THEREOF | 2010 |
|
RU2454406C2 |
| PHARMACEUTICAL COMPOSITION OF ANTIGLYCATING ACTIVITY IN SOLID DOSAGE FORM IN FORM OF CAPSULES AND METHOD FOR PREPARATION THEREOF | 2019 |
|
RU2738804C1 |
| METHOD OF TREATING ACUTE POSTSTREPTOCOCCAL GLOMERULONEPHRITIS IN EXPERIMENT | 2009 |
|
RU2393547C1 |
| APPLICATION OF VACCINIUM AXILLARE NAKAI SHOOTS AS MEDICATION, DEMONSTRATING ACTIVISATION OF GLUCOSE UTILISATION BY BRAIN IN TREATMENT OF DIABETES MELLITUS | 2007 |
|
RU2418602C2 |
| METHOD FOR TREATING WOUNDS | 2020 |
|
RU2758243C1 |
| METHOD OF CORRECTING METABOLIC SYNDROME UNDER EXPERIMENTAL CONDITION | 2022 |
|
RU2806875C1 |
